Completed PHASE3 INTERVENTIONAL 1-arm NCT00185289

Study to Investigate Efficacy and Safety of a New Oral Contraceptive

Multi-center , Open, Uncontrolled Study to Investigate the Efficacy and Safety of a 4 Phasic Oral Contraceptive SH T00658 in a 28-day Regimen for 20 Cycles in Healthy Female Volunteers

Sponsor: Bayer

Conditions Contraception

Interventions EV/DNG (Qlaira, BAY86-5027, SH T00658K)

Updated 7 times since 2017 Last updated: Jul 14, 2011 Started: Apr 30, 2004 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Contraception and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ansbach, Germany , Barcelona, Spain , Berlin, Germany , Bovenden, Germany , Bregenz, Austria , Dietzenbach, Germany , Ettlingen, Germany , Frankfurt am Main, Germany , Fürstenfeld, Austria , Gavà, Spain and 25 more locations